The estimated Net Worth of Charles Cohen is at least $13.4 Million dollars as of 6 July 2021. Charles Cohen owns over 80,000 units of Exelixis Inc stock worth over $6,960,416 and over the last 21 years he sold EXEL stock worth over $6,008,818. In addition, he makes $468,780 as Independent Director at Exelixis Inc.
Charles has made over 13 trades of the Exelixis Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 80,000 units of EXEL stock worth $377,600 on 6 July 2021.
The largest trade he's ever made was selling 248,180 units of Exelixis Inc stock on 14 February 2019 worth over $5,494,705. On average, Charles trades about 17,977 units every 147 days since 2003. As of 6 July 2021 he still owns at least 261,375 units of Exelixis Inc stock.
You can see the complete history of Charles Cohen stock trades at the bottom of the page.
Dr. Charles Jay Cohen Ph.D. serves as Independent Director of the Company. Charles Cohen, Ph.D., has been a director since November 1995. Dr. Cohen is an independent investor and from March 2015 to May 2019, he served as Chief Executive Officer and as a member of the board of directors of Perform Biologics, Inc., a privately held biotechnology start-up company. Previously, Dr. Cohen served as Chief Executive Officer and as a member of the board of directors of On Target Therapeutics, LLC, a privately held biotechnology start-up company, from June 2015 to June 2017. From May 2007 to December 2015, Dr. Cohen was a managing director of Synthesis Capital (formerly Advent Healthcare Ventures), a venture capital firm. From 2003 to 2007, Dr. Cohen was Vice President of Advent International, a global private equity firm. From 2000 to 2002, Dr. Cohen was the Chief Executive Officer of Cellzome AG, a post-genomics biotechnology company. Prior to that time, Dr. Cohen co-founded Creative BioMolecules, Inc., a biotechnology company, in 1982 and was one of its directors and its Chief Executive Officer from 1985 to 1995. Dr. Cohen served as a member of the board of directors of the following publicly held companies: Anadys Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, from 2000 to 2005; and Anesiva, Inc., a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management from 2005 to 2007. Dr. Cohen also served as the Chairman of the Supervisory Board of Cellzome AG, prior to its acquisition by GlaxoSmithKline in May 2012, and as the Chief Executive Officer of several other companies. Dr. Cohen received his B.A. from the State University of New York at Buffalo and his Ph.D. from New York University School of Medicine.
As the Independent Director of Exelixis Inc, the total compensation of Charles Cohen at Exelixis Inc is $468,780. There are 10 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
Charles Cohen is 69, he's been the Independent Director of Exelixis Inc since 1995. There are 5 older and 16 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: